Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IRWD 
Ironwood Pharmaceuticals Inc (IRWD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: IRWD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0.95
1 Year Target Price $0.95
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -57.25% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 251.77M USD | Price to earnings Ratio - | 1Y Target Price 0.95 |
Price to earnings Ratio - | 1Y Target Price 0.95 | ||
Volume (30-day avg) 4 | Beta 0.3 | 52 Weeks Range 0.53 - 5.13 | Updated Date 10/16/2025 |
52 Weeks Range 0.53 - 5.13 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -2.56% | Operating Margin (TTM) 52.88% |
Management Effectiveness
Return on Assets (TTM) 15.53% | Return on Equity (TTM) -574.72% |
Valuation
Trailing PE - | Forward PE 12.33 | Enterprise Value 767335949 | Price to Sales(TTM) 0.82 |
Enterprise Value 767335949 | Price to Sales(TTM) 0.82 | ||
Enterprise Value to Revenue 2.49 | Enterprise Value to EBITDA 9.64 | Shares Outstanding 162434130 | Shares Floating 118078242 |
Shares Outstanding 162434130 | Shares Floating 118078242 | ||
Percent Insiders 2.67 | Percent Institutions 97.42 |
Upturn AI SWOT
Ironwood Pharmaceuticals Inc
Company Overview
History and Background
Ironwood Pharmaceuticals, Inc. was founded in 1998. It is a biopharmaceutical company focused on developing and commercializing innovative medicines to treat gastrointestinal (GI) diseases and address unmet needs.
Core Business Areas
- GI Franchise: Focused on developing and commercializing treatments for gastrointestinal diseases, particularly irritable bowel syndrome with constipation (IBS-C).
- Research and Development: Investing in research to expand pipeline of GI-focused therapies.
Leadership and Structure
Tom McCourt is the current CEO. The company has a typical corporate structure with functional departments like R&D, Commercial, Finance, and Operations.
Top Products and Market Share
Key Offerings
- Linzess/Constella (linaclotide): A guanylate cyclase-C (GC-C) agonist used to treat IBS-C and chronic idiopathic constipation (CIC). Ironwood collaborates with AbbVie (ABBV) in the US and Astellas Pharma globally, excluding China. Linzess holds a significant market share in the branded IBS-C/CIC market. Competitors include Trulance (plecanatide) by Salix Pharmaceuticals, a Bausch Health company (BHC), and generics.
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation, regulatory approvals, and market access. The GI therapeutics market is competitive, with both branded and generic options.
Positioning
Ironwood is a key player in the GI space, focusing on IBS-C and CIC. Its competitive advantage lies in its established product (Linzess) and partnerships with major pharmaceutical companies.
Total Addressable Market (TAM)
The global IBS market is estimated to be over $8 billion. Ironwood, through Linzess, targets a significant portion of the IBS-C and CIC market.
Upturn SWOT Analysis
Strengths
- Established product (Linzess)
- Partnership with AbbVie
- Focus on GI therapeutics
- Experienced management team
Weaknesses
- Reliance on a single key product
- Competition from other IBS-C/CIC treatments
- Patent expiration risks
- Dependence on partneru2019s success for Linzess commercialization
Opportunities
- Expansion of Linzess indications
- Development of new GI therapies
- Strategic acquisitions
- Geographic expansion
Threats
- Generic competition
- Clinical trial failures
- Regulatory changes
- Pricing pressures
Competitors and Market Share
Key Competitors
- BHC
- ABBV
Competitive Landscape
Ironwood's key advantage is its established presence in the IBS-C/CIC market. It faces competition from other pharmaceutical companies with alternative treatments.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to the increasing adoption of Linzess and the effectiveness of its marketing efforts. Has been relatively stable over time.
Future Projections: Future growth is expected to come from continued Linzess sales and potential new product launches. Analyst estimates vary based on market conditions and competitive pressures.
Recent Initiatives: Ironwood has focused on optimizing its commercial operations and advancing its pipeline of GI therapies.
Summary
Ironwood Pharmaceuticals is a mid-sized biopharmaceutical company heavily reliant on Linzess for revenue. Its partnership with AbbVie is crucial for its US market success. Future growth hinges on extending Linzess's market presence and developing new products. Regulatory pressures and competition pose challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions can change rapidly, affecting the accuracy of the data and projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ironwood Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2010-02-03 | CEO & Director Mr. Thomas A. McCourt | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 253 | Website https://ironwoodpharma.com |
Full time employees 253 | Website https://ironwoodpharma.com | ||
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.